Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

被引：0
|
作者：
Strober, Bruce [1 ,2 ]
Paul, Carle [3 ]
Blauvelt, Andrew [4 ]
Thaci, Diamant [5 ]
Elewski, Boni [6 ]
White, Katy [7 ]
Vanvoorden, Veerle [7 ]
Deherder, Delphine [7 ]
Staelens, Fabienne [7 ]
Spelman, Lynda [8 ]
Eyerich, Kilian [9 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Cent Connecticut Dermatol Res, Cromwell, CT USA
[3] Paul Sabatier Univ, Toulouse, France
[4] Oregon Med Res Ctr, Portland, OR USA
[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH 44106 USA
[7] UCB Pharma, Brussels, Belgium
[8] Verac Clin Res, Woolloongabba, Qld, Australia
[9] Tech Univ Munich, Munich, Germany
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [41] Bimekizumab Safety and Efficacy in Patients with Psoriatic Arthritis: 3-Year Results from a Phase 2b Open-Label Extension Study
    Coates, L. C.
    Warren, R. B.
    Ritchlin, C. T.
    Gossec, L.
    Merola, J. F.
    Assudani, D.
    Coarse, J.
    Eells, J.
    Ink, B.
    McInnes, I. B.
    SWISS MEDICAL WEEKLY, 2021, 151 : S20 - S20
  • [42] BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2B OPEN-LABEL EXTENSION STUDY
    Coates, L. C.
    Warren, R. B.
    Ritchlin, C. T.
    Gossec, L.
    Merola, J. F.
    Assudani, D.
    Coarse, J.
    Eells, J.
    Ink, B.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 779 - 780
  • [43] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [44] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [45] Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
    Esteban Daudén
    Pablo de la Cueva
    Laura Salgado-Boquete
    Mar Llamas-Velasco
    Eduardo Fonseca
    Ignasi Pau-Charles
    David Asensio
    Meritxell Guilà
    José Manuel Carrascosa
    Dermatology and Therapy, 2023, 13 : 329 - 345
  • [46] Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
    Dauden, Esteban
    de la Cueva, Pablo
    Salgado-Boquete, Laura
    Llamas-Velasco, Mar
    Fonseca, Eduardo
    Pau-Charles, Ignasi
    Asensio, David
    Guila, Meritxell
    Manuel Carrascosa, Jose
    DERMATOLOGY AND THERAPY, 2023, 13 (01) : 329 - 345
  • [47] Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study
    Yukari Okubo
    Hidetoshi Takahashi
    Ryosuke Hino
    Koki Endo
    Satoru Kikuchi
    Yasushi Ozeki
    Taichi Nakamura
    Maria Paris
    Masatoshi Abe
    Dermatology and Therapy, 2022, 12 : 1469 - 1480
  • [48] Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study
    Paller, Amy
    Pariser, David
    Siegfried, Elaine
    Kricorian, Gregory
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB11 - AB11
  • [49] Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study
    Okubo, Yukari
    Takahashi, Hidetoshi
    Hino, Ryosuke
    Endo, Koki
    Kikuchi, Satoru
    Ozeki, Yasushi
    Nakamura, Taichi
    Paris, Maria
    Abe, Masatoshi
    DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1469 - 1480
  • [50] Five-year open-label extension study of safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis
    Paller, Amy S.
    Siegfried, Elaine C.
    Pariser, David M.
    Rice, Kara Creamer
    Trivedi, Mona
    Iles, Jan
    Collier, David H.
    Kricorian, Greg
    Langley, Richard G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB251 - AB251
12345